67 results
8-K
EX-10.1
IPIX
Innovation Pharmaceuticals Inc.
10 Dec 20
Entry into a Material Definitive Agreement
12:00am
financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company
424B5
IPIX
Innovation Pharmaceuticals Inc.
10 Dec 20
Prospectus supplement for primary offering
12:00am
not take any responsibility for any other information that others may give you. This prospectus supplement is not an offer to sell, nor … in this prospectus or any accompanying prospectus supplement or free writing prospectus, and we take no responsibility for any other information that others
424B5
t0q72mmlvbxthejs
4 Aug 20
Prospectus supplement for primary offering
9:32am
8-K
EX-10.1
3clrmtey
4 Aug 20
Innovation Pharmaceuticals and U.S. Regional Biocontainment Laboratory Nearing Completion of Brilacidin Anti-SARS-CoV-2 (COVID-19) In Vitro Testing
9:29am
POS AM
imo84jfg
17 Oct 19
Prospectus update (post-effective amendment)
5:23pm
POS AM
89bw0z964mn2 knxi
20 Sep 19
Prospectus update (post-effective amendment)
4:35pm
8-K
EX-10.1
fsipccfcl41id60hdvro
22 Jul 19
Entry into a Material Definitive Agreement
9:30am
424B5
mexoazv0qj
10 May 19
Prospectus supplement for primary offering
7:31am
8-K
EX-10.1
30i9zv
9 Oct 18
Innovation Pharmaceuticals Secures Up to $10 Million in Additional Financing to Advance Clinical Pipeline
6:52am
424B5
r9tgls ztbbnkgy7
9 Oct 18
Prospectus supplement for primary offering
6:51am
424B5
h3tln6i peearquuock
29 Jun 18
Prospectus supplement for primary offering
7:23am